BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 21256048)

  • 1. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension.
    Barst RJ; Oudiz RJ; Beardsworth A; Brundage BH; Simonneau G; Ghofrani HA; Sundin DP; Galiè N;
    J Heart Lung Transplant; 2011 Jun; 30(6):632-43. PubMed ID: 21256048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.
    Oudiz RJ; Brundage BH; Galiè N; Ghofrani HA; Simonneau G; Botros FT; Chan M; Beardsworth A; Barst RJ;
    J Am Coll Cardiol; 2012 Aug; 60(8):768-74. PubMed ID: 22818063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tadalafil therapy for pulmonary arterial hypertension.
    Galiè N; Brundage BH; Ghofrani HA; Oudiz RJ; Simonneau G; Safdar Z; Shapiro S; White RJ; Chan M; Beardsworth A; Frumkin L; Barst RJ;
    Circulation; 2009 Jun; 119(22):2894-903. PubMed ID: 19470885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.
    Galiè N; Rubin Lj; Hoeper M; Jansa P; Al-Hiti H; Meyer G; Chiossi E; Kusic-Pajic A; Simonneau G
    Lancet; 2008 Jun; 371(9630):2093-100. PubMed ID: 18572079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
    Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bosentan therapy for pulmonary arterial hypertension.
    Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
    N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
    J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
    Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; McLaughlin VV; Peacock AJ; Simonneau G; Vachiery JL; Grünig E; Oudiz RJ; Vonk-Noordegraaf A; White RJ; Blair C; Gillies H; Miller KL; Harris JH; Langley J; Rubin LJ;
    N Engl J Med; 2015 Aug; 373(9):834-44. PubMed ID: 26308684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
    Channick RN; Olschewski H; Seeger W; Staub T; Voswinckel R; Rubin LJ
    J Am Coll Cardiol; 2006 Oct; 48(7):1433-7. PubMed ID: 17010807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
    Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
    J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
    McLaughlin VV; Oudiz RJ; Frost A; Tapson VF; Murali S; Channick RN; Badesch DB; Barst RJ; Hsu HH; Rubin LJ
    Am J Respir Crit Care Med; 2006 Dec; 174(11):1257-63. PubMed ID: 16946127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tadalafil: in pulmonary arterial hypertension.
    Croxtall JD; Lyseng-Williamson KA
    Drugs; 2010 Mar; 70(4):479-88. PubMed ID: 20205489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.
    King TE; Behr J; Brown KK; du Bois RM; Lancaster L; de Andrade JA; Stähler G; Leconte I; Roux S; Raghu G
    Am J Respir Crit Care Med; 2008 Jan; 177(1):75-81. PubMed ID: 17901413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre.
    Douwes JM; Roofthooft MT; Van Loon RL; Ploegstra MJ; Bartelds B; Hillege HL; Berger RM
    Heart; 2014 Feb; 100(3):224-30. PubMed ID: 24390161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension.
    Zhuang Y; Jiang B; Gao H; Zhao W
    Hypertens Res; 2014 Jun; 37(6):507-12. PubMed ID: 24646647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.
    Galiè N; Beghetti M; Gatzoulis MA; Granton J; Berger RM; Lauer A; Chiossi E; Landzberg M;
    Circulation; 2006 Jul; 114(1):48-54. PubMed ID: 16801459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
    Denton CP; Humbert M; Rubin L; Black CM
    Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.
    Wrishko RE; Dingemanse J; Yu A; Darstein C; Phillips DL; Mitchell MI
    J Clin Pharmacol; 2008 May; 48(5):610-8. PubMed ID: 18305126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan.
    Faruqi S; Fathi H; Morice AH
    Int J Cardiol; 2010 Oct; 144(3):e43-5. PubMed ID: 19171388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era.
    Jacobs W; Boonstra A; Brand M; Rosenberg DM; Schaaf B; Postmus PE; Vonk Noordegraaf A
    J Heart Lung Transplant; 2010 Oct; 29(10):1150-8. PubMed ID: 20580264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.